Ifosfamide in the treatment of non-Hodgkin's lymphoma.
Ifosfamide has been used extensively for the treatment of patients with non-Hodgkin's lymphoma (NHL). This review is limited to published series in which 30 or more evaluable patients were treated in a prospective, uniform fashion either with ifosfamide alone or in combination with other chemotherapeutic agents. Studies in which ifosfamide was used solely as part of a high-dose chemotherapy preparative regimen with autologous hematopoietic progenitor cell transplantation are not included. Three different applications of ifosfamide are addressed: (1) ifosfamide as a single agent and in combination chemotherapy for patients with previously treated NHL, (2) ifosfamide in combination chemotherapy for patients with newly diagnosed, aggressive NHL; and (3) ifosfamide in combination chemotherapy as consolidation for patients with aggressive NHL in first complete remission.
Pohlman
B
B
Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, OH 44195, USA.
D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage / Q000627:therapeutic use*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D011446:Prospective Studies; D012074:Remission Induction; D016879:Salvage Therapy; D014182:Transplantation, Autologous
D018906:Antineoplastic Agents, Alkylating; D007069:Ifosfamide